NEW YORK (GenomeWeb News) – UK protein engineering firm Isogenica today announced it is collaborating with Biolauncher and Cresset Biomolecular Discovery to develop a therapeutic discovery platform.
The partners will integrate expertise in peptide library design, evolutionary screening, next-generation sequencing, structural analysis, and molecular field-based computational chemistry to identify active compounds against high value therapeutic agents. Isogenica said in a statement that the integration of the firms’ technologies "represents a unique platform that can rapidly and cost effectively progress a drug target to structurally diverse small-molecule drug leads without recourse to high-throughput screening."
It added that components of the platform in development have been proven by the partners in collaborations with their own customers. The approach has been shown to be compatible with both extracellular and intracellular targets "enabling a large proportion of the druggable genome to be evaluated." The three companies will next validate the approach with third-party drug targets.
The partners have leveraged non-dilutive funding to integrate the proprietary approaches and will develop and provide access to the system through an open innovation framework, "rather than through more traditional equity structures," Cambridge, UK-based Isogenic said.
Further financial or other terms of the deal were not disclosed.
Based in Cambridge, UK, Biolauncher provides consulting services to life science firms. Cresset is headquartered in Welwyn Garden City, UK, and develops software for calculating and comparing the molecular field characteristics of chemical compounds.